Skip to main content
. Author manuscript; available in PMC: 2009 May 12.
Published in final edited form as: Vaccine. 2008 Mar 27;26(20):2521–2527. doi: 10.1016/j.vaccine.2008.03.005

Table 1.

In vitro growth inhibition assay with anti-AMA1 antibodies against P. falciparum FVO parasitesa

AMA1-rEPA F1/Alhydrogel
AMA1-rEPA F1/Alhydrogel + CPG 7909
Concentration in the Well (mg/ml) 0.8 0.4 0.2 0.8 0.4 0.2
ELISA Units in the Well 4521 2260 1130 12794 6397 3198
% Inhibition 66%b 52% 19% 58%b 53% 29%
a

Mouse sera from the groups immunized with AMA1-rEPA F1/Alhydrogel with and without CPG 7909 at the dose of 0.03 μg were pooled, respectively. Total IgGs were purified from the pooled sera, adjusted to a concentration of 4 mg/ml of IgG and used in the standardized GIA, tested in three 2-fold serial dilutions.

b

This is approximately the plateau value for rodent anti-AMA1 IgGs against FVO parasites since the error in these determinations is ± 10%. Including the data of two previous studies, approximately 55% GIA activity against FVO strain of P. falciparum was achieved when the antibody titers of the mouse derived IgGs to AMA1-FVO was 6000 units, which was close to the maximal GIA level observed (66% GIA activity at 7283 units given by AMA1-rEPA F2/Alhydrogel elicited antibodies) [7, 10].